Eli Lilly and Company, AbbVie, Pfizer, Merck & Co., Inc., Thermo Fisher Scientific, D-Wave Quantum, and AstraZeneca are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are equity shares of publicly traded companies that research, develop, manufacture and sell prescription drugs, vaccines and other medical therapies. Their market value is heavily influenced by factors such as clinical trial outcomes, regulatory approvals, patent expirations and healthcare policy changes, making them prone to higher volatility but potentially offering significant growth for investors focused on healthcare innovation. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE:LLY traded up $0.32 on Friday, hitting $779.60. The company had a trading volume of 1,450,772 shares, compared to its average volume of 3,664,838. The business has a 50 day moving average of $773.61 and a 200 day moving average of $799.72. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a market cap of $738.85 billion, a PE ratio of 63.43, a PEG ratio of 1.14 and a beta of 0.40. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.
Read Our Latest Research Report on LLY
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of AbbVie stock traded down $1.25 during trading hours on Friday, reaching $189.50. The stock had a trading volume of 3,706,217 shares, compared to its average volume of 6,248,905. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. AbbVie has a 1 year low of $163.63 and a 1 year high of $218.66. The firm has a market capitalization of $334.73 billion, a price-to-earnings ratio of 80.64, a P/E/G ratio of 1.26 and a beta of 0.48. The firm has a 50 day simple moving average of $187.37 and a two-hundred day simple moving average of $188.46.
Read Our Latest Research Report on ABBV
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
NYSE:PFE traded up $0.13 during trading hours on Friday, reaching $25.45. 27,104,580 shares of the stock were exchanged, compared to its average volume of 41,625,077. The stock has a market capitalization of $144.66 billion, a P/E ratio of 18.44, a P/E/G ratio of 0.92 and a beta of 0.58. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a 50 day simple moving average of $23.72 and a 200-day simple moving average of $24.83.
Read Our Latest Research Report on PFE
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Merck & Co., Inc. stock traded down $1.42 during mid-day trading on Friday, hitting $80.97. 7,734,538 shares of the company's stock traded hands, compared to its average volume of 13,256,132. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $129.93. The company has a market cap of $203.32 billion, a PE ratio of 11.79, a price-to-earnings-growth ratio of 0.84 and a beta of 0.39. The firm has a 50 day moving average price of $79.20 and a 200 day moving average price of $87.05. The company has a quick ratio of 1.16, a current ratio of 1.41 and a debt-to-equity ratio of 0.69.
Read Our Latest Research Report on MRK
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of Thermo Fisher Scientific stock traded up $0.49 during midday trading on Friday, hitting $428.25. The company's stock had a trading volume of 1,359,321 shares, compared to its average volume of 1,971,505. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $627.88. The stock has a 50-day simple moving average of $409.18 and a 200-day simple moving average of $479.90. The firm has a market capitalization of $161.66 billion, a P/E ratio of 25.12, a PEG ratio of 2.28 and a beta of 0.77. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.
Read Our Latest Research Report on TMO
D-Wave Quantum (QBTS)
D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.
QBTS traded up $0.65 on Friday, hitting $16.63. 29,876,920 shares of the stock traded hands, compared to its average volume of 48,043,095. D-Wave Quantum has a 52 week low of $0.75 and a 52 week high of $19.77. The firm has a market capitalization of $4.86 billion, a PE ratio of -27.72 and a beta of 1.40. The business has a fifty day moving average price of $14.08 and a two-hundred day moving average price of $9.38. The company has a current ratio of 20.73, a quick ratio of 20.61 and a debt-to-equity ratio of 0.15.
Read Our Latest Research Report on QBTS
AstraZeneca (AZN)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Shares of AZN traded down $1.53 on Friday, hitting $69.60. The company's stock had a trading volume of 6,768,010 shares, compared to its average volume of 5,252,689. The company has a 50 day moving average price of $70.78 and a 200 day moving average price of $70.60. AstraZeneca has a fifty-two week low of $61.24 and a fifty-two week high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. The company has a market capitalization of $215.85 billion, a PE ratio of 27.95, a PEG ratio of 1.28 and a beta of 0.37.
Read Our Latest Research Report on AZN
Featured Stories
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
